Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
Journal: British journal of haematology
Published: February 13, 2020
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Journal: Haematologica
Published: January 27, 2020
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
Journal: Bone marrow transplantation
Published: January 23, 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2018
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 23, 2015
Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: February 17, 2015
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 13, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026